|
News Focus December 15, 2009 Contact: Ms Nadjet Amaroui Rockland Technimed Ltd and NUKEM GmbH will be exhibiting at the upcoming joint meeting of ISMRM-ESMRMB in Stockholm, Sweden starting May 1 thru-7th, 2010. The exhbit booth is 370. In addition we will be holding our Oxy-17 Users Group meeting Dinner Symposium on Tuesday May 4th 2010. For any information please contact us at Tel: +1-845-426-3406 , Fax +1-845-436-1109 Email: staff@technimed.com Regulatory News Focus: US Food and Drug Administration, Dec 22, 2006:Public Health Advisory Update on Magnetic Resonance Imaging (MRI) Contrast Agents Containing Gadolinium and Nephrogenic Fibrosing Dermopathy. Link to US FDA Public Advisory Health Canada Advises Canadians of Safety Issues Related to Gadolinium-Containing Contrast Agents Used in Magnetic Resonance Imaging (MRI)Link to Canada Health Advisory UK.MHRA-Medicines and Healthcare products Regulatory Agency -Nephrogenic Systemic Fibrosis (NSF) and gadolinium-containing MRI contrast agentsRelated links: Internal Medicine News Vol 4 No 2 Nature Clinical Practice Nephrology Vol 3 No 2
|
|
|
|||||
|
|||||||
|
|
||||||
Rockland Technimed Ltd. |
|||||||
|
Oxy-17® is a registered Trade Mark of Rockland Technimed Ltd for: Oxygen-based diagnostic agents, preparations and substances for medical purposes, namely, contrast media for medical imaging for use with MRI diagnostic apparatus, and diagnostic scanning agents in the nature of contrast media for use in In-Vivo imaging. |
|||||||
